Data ExclusivitiesPatents Drug Exclusivities in the US: Is it Justified? (Part 2 of 2)June 25, 2020 This is Part 2 of a two-part Article. In Part I, I dealt with Henry…Bhavik Shukla Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla Latest Posts Search Blog Front Page BLOG POSTS Stopping the Spread of Counterfeit Medicine in the Age of COVID-19 Patent Pools: An Attempt to Reinforce the Status Quo and Private Ordering Beyond Data Exclusivities: Redefining Access to “Necessary Data” in the Era of COVID-19 Is it Time to Do Away with Data Exclusivity? IP barriers in tackling COVID 19: Anything in TRIPS to help out? CATEGORIES COVID-19 10 Data Exclusivities 3 Exhaustion 2 Experimental Use 1 IPAB 1 Patent Pools 1 Patents 11 Trade Policy 1 TRIPS 10 TRIPS Flexibilities 2 Voluntary Licenses 1
Data ExclusivitiesPatents Drug Exclusivities in the US: Is it justified? (Part 1 of 2)June 25, 2020 This is Part 1 of a two-part Article. Data and market exclusivities, often termed as…Bhavik Shukla
